Resources

In this exclusive interview from ADA Dr. Israel Hodish discusses the provocative topic "Why insulin therapy doesn't work and what we can do about it," with Steve Freed.

Dr. Israel Hodish talks with Diabetes in Control Publisher Steve Freed at the 2016 ADA Meeting about his ADA presentation on the outcome of patients using insulin and why insulin therapy doesn't work.

In this week's Homerun Slides, the implications for practice and conclusion of the EMPA-REG Outcome Trial.

PI-3 kinase-independent pathways for stimulation of glucose transport: The CAP/Cbl/TC10 pathway. Substantial evidence confirms the presence of PI-3 kinase independent pathways for stimulation of glucose transport. It had long been clear that other growth factor receptors (i.e., the platelet-derived growth factor (PDGF) receptor, cytokine receptors such as IL-4, and certain integrins) activate PI-3 kinase to the same extent as the insulin receptor with generation of PI(3,4,5)P3, yet still do not stimulate glucose transport.

For a newly diagnosed type 2 patient with an elevated A1c of 7-8%, would you consider an SGLT-2 drug as a second treatment option added to metformin if they are not at goal on metformin? Follow the link to share your opinion and see what your colleagues think!

New research finds issue in the setting of dehydration and/or during use of nonsteroidal anti-inflammatory agents (NSAIDs) or radiocontrast studies.

Investigation supports that early diabetes has lower thromboembolic risk than later.

Survey estimates that diabetes accounts for many more deaths in the United States than are being reported on death certificates — and that diabetes is actually the third leading cause of death.

Phase-3 study to evaluate efficacy and safety of ertugliflozin monotherapy.

A new study suggests that people who spend time walking or even just standing instead of sitting may be at lower risk of type 2 diabetes.